The history of copyright's flagship drug presents a nuanced case for investors in the pharmaceutical sector. While initially a tremendous success, producing vast sums, the intellectual property end and the subsequent arrival of generic competitors have considerably affected income. This presents questions about the ongoing viability of similar drug